Ology Bioservices will develop the large-scale, process development and manufacturing plan and supply the AnAPN1 vaccine candidate for use in ongoing pre-clinical studies and to prepare for subsequent clinical testing.
Ology Bioservices Strengthens Board of Directors with Appointment of Industry Veterans James M. Robinson and Gerard Cunningham Former Merck & Co. Executives Bring Deep Expertise in Development and Manufacturing of Vaccines and Biologicals ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices, Inc., a biologics-focused contract development and manufacturing organization (CDMO) serving both government and commercial clients, [...]
Nanotherapeutics Announces Name Change to Ology Bioservices, Reflecting the Company’s Ongoing Transformation into One of the Top Contract Development and Manufacturing Organizations of Vaccines and Biologics ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, Inc. today announced that the Company has changed its name to Ology Bioservices, Inc., effective immediately. The name change is part of a [...]
ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, Inc., a biologics focused contract development and manufacturing organization (CDMO), today announced that Peter H. Khoury, Ph.D., MBA, formerly Senior Vice President and Chief Commercial Officer, has been appointed President and Chief Executive Officer of the Company.
ALACHUA, Fla. & PUNE, India--(BUSINESS WIRE)--Nanotherapeutics Bohumil s.r.o. (a wholly owned subsidiary of Nanotherapeutics, Inc.) and Cyrus Poonawalla Group announced today the final transfer of Nanotherapeutics Bohumil s.r.o.’s vaccine production enterprise located in Bohumil, Czech Republic to Praha Vaccines a.s. Read the full article at Business Wire
Battelle and Nanotherapeutics, Inc. announced today that the organizations have entered an alliance to bring together core research, development, test and evaluation (RDT&E) and manufacturing capabilities needed to expedite the development of medical countermeasures urgently required by the Department of Defense (DoD) to protect deployed military forces from Chemical, Biological, Radiological and Nuclear (CBRN) threats.Read [...]
Trethera Corporation and Nanotherapeutics Sign Exclusive Worldwide Agreement for Rights to Triapine® in Hematological Malignancies SANTA MONICA, Calif. & ALACHUA, Fla.--(BUSINESS WIRE)--Trethera Corporation and Nanotherapeutics, Inc. today announced the signing of an exclusive worldwide agreement whereby Nanotherapeutics has granted Trethera an exclusive license for the global development, manufacturing and marketing of Triapine® [...]
Nanotherapeutics Appoints Prasad Raje, Ph.D. as President and Chief Executive Officer ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, Inc., a contract development and manufacturing organization (CDMO), announced today that Prasad Raje, Ph.D., has been appointed President and Chief Executive Officer, succeeding James M. Matthew, who served as interim President and Chief Executive Officer and will retain [...]
Nanotherapeutics to Present at 28th Annual Piper Jaffray Healthcare Conference ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, Inc., a contract development and manufacturing organization (CDMO), announced today that management will give a corporate presentation at the 28th Annual Piper Jaffray Healthcare Conference. Additional information is as follows: Date: Wednesday, [...]
ALACHUA, FL, September 20, 2016 (BUSINESSWIRE) - Nanotherapeutics, Inc., a contract development and manufacturing organization (CDMO), announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the company a contract for advanced biologics manufacturing services as part of a multiple award IDIQ (Indefinite Delivery/Indefinite Quantity) pool. The contract has a maximum ceiling of $159.4 million and a performance period of up to 10 years.